| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8736987 | Current Opinion in Immunology | 2018 | 7 Pages |
Abstract
Filoviruses, including ebolaviruses and marburgviruses, are the causative agents of highly lethal disease outbreaks. The 2013-2016 Ebola virus outbreak was responsible for >28Â 000 infections and >11Â 000 deaths. Although there are currently no licensed vaccines or therapeutics for any filovirus-induced disease, monoclonal antibodies (mAbs) are among the most promising options for therapeutic development. Hundreds of mAbs have been isolated from human survivors of filovirus infections that target the viral spike glycoprotein (GP). The binding, neutralization, and cross-reactivity of many of these mAbs has been determined. Several mAbs have been characterized structurally, and this information has been crucial for strategizing therapeutic and vaccine design. Here we present an overview of the structural features of the neutralizing/protective epitopes on filovirus glycoproteins.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Liam B King, Brandyn R West, Sharon L Schendel, Erica Ollmann Saphire,